Literature DB >> 22157808

Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1.

P Liu1, B Xu, W Shen, H Zhu, W Wu, Y Fu, H Chen, H Dong, Y Zhu, K Miao, W Xu, J Li.   

Abstract

Impaired cell death program has been noted as one of the hallmarks of chronic lymphocytic leukemia (CLL) and contributes to its accumulation of malignant monoclonal B cells as well as to chemotherapy resistance. A cell can die through the apoptosis or necrosis pathway. Recent investigations suggest that in apoptotic-deficient conditions, such as most types of cancer, a process of programmed necrosis, called necroptosis, prevails. However, the detailed molecular mechanisms underlying this alternative cell death pathway are still not fully understood. Here we demonstrate that CLL cells failed to undergo necroptosis upon stimulation of TNFα combined with pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD). Two core components of necroptotic machine, RIP3 and deubiquitinase cylindromatosis (CYLD), are markedly downregulated in CLL. Moreover, we identified lymphoid enhancer-binding factor 1 (LEF1), a downstream effector of the Wnt/β-catenin pathway, as a transcription repressor of CYLD in CLL. Knocking down LEF1 sensitizes CLL cells to TNFα/zVAD-induced necroptosis. The present investigation provides the first evidence that CLL cells have defects not only in apoptotic program but also in necroptotic signaling. Targeting the key regulators of necroptotic machine, such as LEF1, to restore this pathway may represent a novel approach for CLL treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22157808     DOI: 10.1038/leu.2011.357

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  50 in total

Review 1.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 2.  Necroptosis: A new way of dying?

Authors:  Britt Hanson
Journal:  Cancer Biol Ther       Date:  2016-07-19       Impact factor: 4.742

Review 3.  The mechanism of necroptosis in normal and cancer cells.

Authors:  Simone Fulda
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

Review 4.  Relevance of necroptosis in cancer.

Authors:  Najoua Lalaoui; Gabriela Brumatti
Journal:  Immunol Cell Biol       Date:  2016-12-06       Impact factor: 5.126

Review 5.  CYLD-mediated signaling and diseases.

Authors:  Bryan J Mathis; Yimu Lai; Chen Qu; Joseph S Janicki; Taixing Cui
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

6.  Necroptosis, the Other Main Caspase-Independent Cell Death.

Authors:  Larissa C Zanetti; Ricardo Weinlich
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Authors:  L Ouyang; Z Shi; S Zhao; F-T Wang; T-T Zhou; B Liu; J-K Bao
Journal:  Cell Prolif       Date:  2012-10-03       Impact factor: 6.831

8.  Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

Authors:  Lili Wang; Alex K Shalek; Mike Lawrence; Ruihua Ding; Jellert T Gaublomme; Nathalie Pochet; Petar Stojanov; Carrie Sougnez; Sachet A Shukla; Kristen E Stevenson; Wandi Zhang; Jessica Wong; Quinlan L Sievers; Bryan T MacDonald; Alexander R Vartanov; Natalie R Goldstein; Donna Neuberg; Xi He; Eric Lander; Nir Hacohen; Aviv Regev; Gad Getz; Jennifer R Brown; Hongkun Park; Catherine J Wu
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

9.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

10.  SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Authors:  Cinzia Bologna; Roberta Buonincontri; Sara Serra; Tiziana Vaisitti; Valentina Audrito; Davide Brusa; Andrea Pagnani; Marta Coscia; Giovanni D'Arena; Elisabetta Mereu; Roberto Piva; Richard R Furman; Davide Rossi; Gianluca Gaidano; Cox Terhorst; Silvia Deaglio
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.